SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

MFI is trending due to a significant price surge following the announcement of a $500M private placement to fund a digital asset treasury strategy, specifically Bitcoin Cash (BCH). The community is actively debating the company's strategic shift into crypto, the potential for dilution from the new share issuance, and whether this is a sustainable move or a classic pump-and-dump scheme, especially given MFI's history and the volatile nature of digital asset investments.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending as investors eagerly await topline data from its Phase 3 HOPE-3 trial, with community chatter focused on potential outcomes and FDA approval scenarios. Discussions include the possibility of a short squeeze and speculation around the timing of the data release, expected in the coming weeks. Community members are weighing the potential for positive results in treating Duchenne Muscular Dystrophy and the impact on the company's future.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as investors react to the company's AI strategy and substantial debt, with community discussions focusing on potential risks and opportunities. Concerns about rising credit-default swap costs and reliance on OpenAI are being weighed against Oracle's ongoing investments in AI infrastructure. Investor sentiment appears divided, with some seeing a buying opportunity amid the recent selloff, while others express skepticism about the company's long-term prospects.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding Company ($SCLX) is trending amid discussions about its relationship with Datavault AI ($DVLT) and a proposed meme coin dividend for shareholders. The community is focused on the potential for a short squeeze, driven by the mechanics of the dividend distribution and related obligations for short sellers. Some investors express concerns about company management and financial strategy.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors weigh a potential bounce against persistent headwinds. Community members are closely watching for news on the union strike vote and its impact on production, while also considering the recent analyst downgrade and general market weakness. Despite positive order news, concerns linger about execution, profitability, and ongoing certification delays.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly's stock is trending as it approaches a $1 trillion market cap, fueled by excitement around its diabetes and weight-loss drugs like Mounjaro and Zepbound. Community discussions revolve around the company's potential for further growth and possible stock splits, as well as its competition with other players in the GLP-1 market. Some traders are taking profits, while others anticipate continued upward momentum, drawing comparisons to tech giants and speculating about future catalysts.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending as traders discuss its regained NASDAQ compliance, drawing parallels to other Hong Kong-based stocks that have recently experienced significant gains. A substantial contract is noted as a potential catalyst, while community members actively speculate on a potential short squeeze due to the stock's low float and high cost to borrow.

Enviri Corp. engages in the provision of industrial services and engineered products. It operates through the following segments: Harsco Environmental, Clean Earth, and Harsco Rail. The Harsco Environmental segment offers on-site services, under long-term contracts which may contain multiple performance obligations. The Clean Earth segment refers to specialty waste processing and beneficial reuse solutions for hazardous wastes, and soil and dredged materials. The Harsco Rail segment sells railway track maintenance equipment, after-market parts and safety and diagnostic equipment. The company was founded in 1853 and is headquartered in Philadelphia, PA.

Enviri Corp

Harsco Corp.

Shares of NVRI are trending after the company announced the sale of its Clean Earth business to Veolia for $3.04 billion and a spin-off of its other businesses into a new entity. The community is discussing the potential per-share value for shareholders following the deal, with some estimating significant upside. Some traders are watching for breakout levels and potential profit-taking opportunities.

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Palatin Technologies Inc.

Palatin Technologies ($PTN) is trending due to significant volatility and community discussion around a recent run-up and subsequent trading halts. Chatter revolves around whether the stock is a low-float rocket or a pump and dump, with some highlighting insider buying as a positive sign, while others point to dilution concerns and the company's history.

CCH Holdings Ltd. engages in operating a chicken restaurant. It offers catering services in Malaysia and outside Malaysia under the brand name, Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. The company was founded by Goh Kok Foong on December 2, 2024 and is headquartered in Seberang Perai, Malaysia.

CCH Holdings Ltd

CCHH is trending as traders discuss its recent climb since its October IPO, with some anticipating further gains. The community is debating potential price targets and speculating on whether the stock is being manipulated for a pump-and-dump scheme. Some traders are taking profits, while others suggest holding for a possible run to double digits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Look Abroad? Global Equity ETFs to Consider

Stretched U.S. valuations and AI bubble fears have investors looking abroad and are driving interest in international equity and emerging market ETFs.

Don't Go All-In on Tech: Diversify With These ETFs  

As bubble fears rise and volatility spikes, investors can turn to ETFs like RSP, GLD and IEMG to diversify and cut concentration risk.

Feeling Tech-Heavy? Diversify With These ETFs Amid AI Bubble Concerns

Wall Street warns of an AI equity bubble as mega-cap tech surges, prompting investors to diversify into ETFs for balanced growth.

Should Investors Pivot to Global Equity ETFs for Wider Market Exposure?

Investors can eye global equity funds as AI bubble fears, U.S. market risks and Fed easing fuel demand for international diversification.

Danish drugmaker Novo Nordisk (NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site, which produces its blockbuster Semaglutide drugs.According to a Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/world-at-work/novo-nordisk-cuts-hit-production-line-jobs-key-us-plant-posts-show-2025-10-07/">report</a>, citing a review of LinkedIn posts, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton, North Carolina, plant and other facilities in the state. It also includes a strategic communications manager and an HR assistant, the report added.The Clayton facility makes Semaglutide, the active ingredient in the company’s blockbuster Wegovy and Ozempic. It also does steps including filling, finishing, and packaging the injections. It will also play a part in the production of the pill version of Wegovy once available, Reuters noted.Notably, Novo announced layoffs in September and forecast billions in annual savings. The company had said that it would cut 9,000 positions, or about 11.5% of its 78,400-strong global workforce, as part of a company-wide transformation. About 5,000 roles will be eliminated in Denmark, it said.The restructuring is expected to save eight billion Danish crowns ($1.26 billion) annually by 2026 and will focus resources on diabetes and obesity, Novo’s key growth areas. Reuters noted that the exact reason and number for layoffs in Clayton are unclear.Shares of NVO stock fell 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘neutral’ territory over the past 24 hours, and message volume stayed within ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1364/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_7_12_09_AM_png_2205cacccb.webp" alt="NVO's Sentiment Meter and Message Volume as of 7:10 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1364" height="120"><figcaption>NVO's Sentiment Meter and Message Volume as of 7:10 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>NVO stock fell 31% this year and by about 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grrr-shares-rally-over-4-percent-pre-market-retail-says-stock-should-be-trading-over-40/ch6PBTQR3Wu">GRRR Shares Rally Over 4% Pre-Market, Retail Says Stock Should Be Trading Over $40: ‘Unbelievable! Way, Way Undervalued’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant

According to a Reuters report, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton plant. 

Equity

According to a Reuters report, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton plant. 


Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

Diversify With ETFs and Stay Ahead in Volatile Markets

Amid AI bubble worries and tech sell-offs, investors turn to value, consumer staples, gold and international ETFs for diversification.

Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered forecast, Bloomberg reported on Friday, citing a company spokesperson.The reduction will apply to employees who are eligible for short-term incentives in Denmark, the report <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-22/novo-to-cut-employee-bonuses-in-denmark-due-to-slower-growth?srnd=homepage-americas">added</a>. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">Novo</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. Shares of the company traded 3% higher in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:574/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_8_54_27_AM_png_454a11d7f9.webp" alt="NVO's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="574" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they expect the stock to hit $80 by the end of the year.<stembedurl>https://stocktwits.com/WallstreetPatron43/message/626170781</stembedurl>Another user said that they expect a lot of shorting on Friday.<stembedurl>https://stocktwits.com/oldmanrizzer/message/626170959</stembedurl>Earlier this week, it was <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">reported</a> that the drugmaker has implemented a hiring freeze, which will apply across all markets and departments, with an exemption for business-critical roles. Former CEO of Novo Nordisk, Lars Fruergaard Jørgensen, said earlier this month that the company is taking measures to sharpen its commercial execution further, and ensure efficiencies in cost base while continuing to invest in future growth. Novo’s new CEO, Maziar Mike Doustdar, took charge on August 7.Last month, the company, battling competition from its U.S. rival Eli Lilly, lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.NVO stock is down by 36% this year and by 59% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-sees-near-50-percent-upside-on-ehang/chsZcIERd0M">JPMorgan Sees Near 50% Upside On This Chinese eVTOL Maker: Retail Believes There’s A Lot To Look Forward To</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Novo Nordisk To Reportedly Cut Yearly Bonus For Denmark Employees: Retail Expects Stock To Hit $80 By Year-End

According to Bloomberg, the reduction in bonuses will apply to employees who are eligible for short-term incentives in Denmark.

Retail sentiment around Anheuser-Busch InBev (ABI),&nbsp;the maker of Budweiser and Corona beers, ticked higher, even as a weak quarterly report sent its shares sliding on Thursday.<a href="https://stocktwits.com/symbol/BUD">BUD's U.S.-listed shares</a> dropped over 13%&nbsp;in the previous session, marking their worst day in over five years.On Stocktwits, retail sentiment&nbsp;shifted to 'extremely bullish' by early Friday, up from 'bullish' the day before, as traders&nbsp;viewed the slide as an overreaction and saw it as a buying opportunity. Message volume for BUD rose 1,200% in the past 24-hour period, among the highest for a consumer stock.<figure class="image"><img style="aspect-ratio:1256/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_12_48_05_PM_png_fd95800c98.webp" alt="Screenshot 2025-08-01 at 12.48.05 PM.png" width="1256" height="156"><figcaption>BUD sentiment and message volume as of August 1 | Source: Stocktwits</figcaption></figure>"Not a fan of the company, but this drop is a bit unjustified," said one user<stembedurl>https://stocktwits.com/Reddiot/message/623258303</stembedurl>Another said: "$BUD Buying dat dip, 10% discount? Thank you!" A third user shared a technical chart showing the stock hitting a key long-term support level.<stembedurl>https://stocktwits.com/stocksailor23/message/623228047</stembedurl><stembedurl>https://stocktwits.com/theoptionsplug/message/623173574</stembedurl>AB InBev said revenue grew 3% organically in the second quarter, below market expectations of 3.2% growth. Organic sales volumes, however, were down 1.9%,&nbsp;primarily due to weak sales in Brazil and China, marking the&nbsp;ninth consecutive quarter of declining beer sales.&nbsp;That was significantly below the 0.3% decline analysts had expected.Organic operating profit increased by 6.5%, ahead of analysts' forecasts of 5.7%.The world's largest brewer also reported weaker-than-expected volumes in Europe and the Middle East,&nbsp;which led to disappointment in all regions except North America.A rebound in the home market comes even as beer demand softens in the region. Bank of America has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bof-a-downgrades-miller-lite-brewer-molson-coors-amid-softness-in-us-beer-sales/chmZESFRReS">predicted</a> that U.S. beer volumes will shrink by 4% next year, steeper than its earlier prediction of 1% decline.In early July, AB InBev&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/budweiser-maker-ab-inbev-plans-300m-investment-to-expand-us-production/chi8fifRbZd">announced</a> plans to invest $300 million in its U.S. manufacturing operations this year, aligning with the Trump administration's broader push for domestic production.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/Starbucks-china-operations-jd-tencent-kkr-among-potential-investors/chr3YU9RdGt">Starbucks China Operations: JD, Tencent, KKR Among Potential Investors To Submit Bids - Report</a>

In this photo illustration, Budweiser beer bottles are seen displayed. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Budweiser Maker’s Stock Gets Crushed After Q2 Gloom — Retail Traders Feel 'Drop Is A Bit Unjustified'

U.S.-listed shares of the world's largest brewer marked their worst day in over five years after the company missed revenue and volume estimates.

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) decision on Wednesday to remove Novo Nordisk's popular drugs, Ozempic and Wegovy, from its shortage list.Pittman said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list while rejecting a challenge brought by compounding pharmacies who sought to continue making copies of the drugs, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-judge-upholds-fdas-removal-ozempic-wegovy-drug-shortage-list-2025-06-18/">reported</a>.Compounders are allowed to produce copies of drugs only when they are declared to be in short supply by the FDA. In February, the FDA announced that the semaglutide injection product shortage had been resolved, preventing compounders from manufacturing copies of Wegovy and Ozempic, as semaglutide is the active ingredient in them.Semaglutide injection products were first added to the FDA’s drug shortage list in 2022, paving the way for compounders to replicate them.Late last month, Novo Nordisk said that it had filed nearly 120 lawsuits across 34 states against compounders and other entities making false and misleading claims about their “semaglutide" drugs.The company also announced a $199-per-month limited-time offer for self-paying patients new to its weight loss drug, Wegovy, to encourage patients who previously used compounded versions of the drug to transition to Wegovy.On Stocktwits, retail sentiment around Novo Nordisk shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_12_40_07_PM_png_8852be04e7.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits" width="629" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 15% this year and by about 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tmc-stock-surges-to-near-4-year-high-after-opening-the-door-to-cashless-exercise-of-class-b-warrants/chlsB67RR2h">TMC Stock Surges To Near 4-Year High After Opening The Door To Cashless Exercise Of Class B Warrants</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 

AVDE
American Century ETF Trust - Avantis International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AVDE News

AVDEAmerican Century ETF Trust - Avantis International Equity ETF